Chromocell Therapeutics Corporation (CHRO NYSE MKT) stock market data APIs
$1.351
-0.09(-6.7%)
as of June 11, 2025
Try our APIs with
free plan!
Chromocell Therapeutics Corporation Financial Data Overview
Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body's peripheral nervous system. The company's lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and idiopathic small fiber neuropathy. It also develops CT2000 as a topical agent for the treatment of both acute and chronic eye pain; and CT3000 to treat post operative pain with the use of nerve blocks. The company was Chromocell Therapeutics Corporation and changed its name to Channel Therapeutics Corporation in November 2024. Channel Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Prev. Close
1.351
Open
1.2653
High
1.3865
Low
1.2573
52 wk Range
0.45-3.8
Market Cap
8 904 K
Shares Outstanding
6 596 K
EPS
-0.29
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Chromocell Therapeutics Corporation data using free add-ons & libraries
Get Chromocell Therapeutics Corporation Fundamental Data
Chromocell Therapeutics Corporation Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-27
- EPS/Forecast: -0.23
Get Chromocell Therapeutics Corporation End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Chromocell Therapeutics Corporation News
New
Tandem Diabetes, Roche enter patent settlement agreement
In a regulatory filing, Tandem Diabetes Care (TNDM) disclosed that Tandem and Roche (RHHBY) entered into a Settlement, Mutual Release and Cross-License Agreement to resolve all actual or potential pat...
LGND: Pelthos To Become Public Company
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) announced that it had identified a suitor to take its subsidiary Pelthos Therapeu...
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Channel Therapeutics Corporation (NYSE:CHRO) on Thursday signed a definitive merger agreement to combine Ligand’s wholly owned subsidiaries, Pel...
CEO Alex Rodriguez Interviews on The Chron Organization’s Organic Growth and the Potential of the Zero Cost Program™
Dallas, TX. , Sept. 26, 2017 (GLOBE NEWSWIRE) -- Alex Rodriguez CEO of The Chron Organization (OTCQB: CHRO) interviews on the Uptick Network Stock Day Podcast with host Everett Jolly. In the beginni...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
